Video

ASCO 2013 Genitourinary Cancers Symposium wrap up


 

The 2013 ASCO Genitourinary Cancers Symposium was more about expansion of knowledge than major practice changers. In an interview Dr. Nicholas Vogelzang of the Comprehensive Cancer Centers of Nevada touches upon this year's major studies on GU cancers and predicts what's in the store for the coming year.

Recommended Reading

Medicare policy change led to higher drug spending
MDedge Hematology and Oncology
FDA approves abiraterone use ahead of prostate cancer chemotherapy
MDedge Hematology and Oncology
FDA proposal encourages development of abuse deterrent opioids
MDedge Hematology and Oncology
Discussing prostate cancer treatment options
MDedge Hematology and Oncology
Prostatectomy vs. radiotherapy: 15-year functional outcomes are same
MDedge Hematology and Oncology
Job stress not linked with cancer risk
MDedge Hematology and Oncology
Age, race impact prostate cancer risk
MDedge Hematology and Oncology
Shorter androgen blockade okay in localized prostate cancer
MDedge Hematology and Oncology
Survival higher with surveillance of small kidney tumors
MDedge Hematology and Oncology
Abiraterone reduced morbidity in mCRPC patients
MDedge Hematology and Oncology